Executive Director Hematologic Cancer Research @SarahCannonDocs @SCRIOncology #Duke alum. Tweets my own, not medical advice. #cll #lymsm
Nashville, TN
Joined November 2013
- Tweets400
- Following323
- Followers960
- Likes1.2K
Krish Patel retweeted
Congratulations to @IMFmyeloma on the launch of the US Myeloma Network! We are honored to serve as the CRO and support clinical trials designed to advance research and expand opportunities for patients w/ multiple myeloma. Looking forward to this collaboration in #CancerResearch.
I am proud to announce the launch of the US Myeloma Network (USMN) by the International Myeloma Foundation. @IMFmyeloma
The USMN will conduct clinical trials including phase III randomized controlled trials. @JNJInnovMed is our first industry partner. @SarahCannonDocs will be our CRO.
@SagarLonialMD @TomMartinMD @szusmani @myelomaMD @NikhilMunshiMD
prnewswire.com/news-releases…
Krish Patel retweeted
I am proud to announce the launch of the US Myeloma Network (USMN) by the International Myeloma Foundation. @IMFmyeloma
The USMN will conduct clinical trials including phase III randomized controlled trials. @JNJInnovMed is our first industry partner. @SarahCannonDocs will be our CRO.
@SagarLonialMD @TomMartinMD @szusmani @myelomaMD @NikhilMunshiMD
prnewswire.com/news-releases…
Krish Patel retweeted
At #ESMO26, SCRI will present 85+ abstracts and presentations across antibody drug conjugates, immunotherapies, and bispecific antibodies, with work from 40 authors across our network of research sites. scri.com/news/sarah-cannon-r…
A pleasure to sit down with @TargetedOnc and talk about how important conducting clinical trials in community oncology settings is. So many opportunities to accelerate advancements for patients. So fortunate I get to do this work every day at @SarahCannonDocs @SCRIOncology
Decentralized and intentionally-designed oncology trials are essential to expanding access; even more, Krish Patel, MD (@SarahCannonDocs) believes that they shouldn't be a last resort.
Read the full interview: targetedonc.com/view/purpose…
#Oncology #ClinicalTrials | @KrishPatelMD
Krish Patel retweeted
Decentralized and intentionally-designed oncology trials are essential to expanding access; even more, Krish Patel, MD (@SarahCannonDocs) believes that they shouldn't be a last resort.
Read the full interview: targetedonc.com/view/purpose…
#Oncology #ClinicalTrials | @KrishPatelMD
Krish Patel retweeted
For #BloodCancerAwarenessMonth, @KrishPatelMD (@SarahCannonDocs) sat down with us to talk about the evolving world of T‑cell immunotherapies.
💬 Read part 1 of the interview: targetedonc.com/view/expandi…
#Immunotherapy #Leukemia #Lymphoma #BloodCancer #Hematology #Oncology
Krish Patel retweeted
In a recent interview w/ @Blood_Cancers, Dr. Hans Lee of @SCRIOncology discusses how cellular therapies are changing care for patients with advanced multiple myeloma and the importance of expanding access.
Read the Q&A:
The next step in advanced #myeloma is improving access to therapies such as CAR-T and bispecific antibodies, according to Hans Lee, MD, of @SarahCannonDocs.
📖 Read more from this exclusive Q&A: buff.ly/5qX7rQu
Krish Patel retweeted
SCRI's Dr. @ErikaHamilton9 shares key #ASCO2026 breast cancer updates with @VJOncology . Watch to learn more: vjoncology.com/video/sqquthw…
#BreastCancer #Oncology #ClinicalResearch
Krish Patel retweeted
Join us TOMORROW!
Webinar: Understanding and Accessing Chimeric Antigen Receptor (CAR) T-Cell Therapy, in partnership with @SarahCannonDocs
Featuring @KrishPatelMD
Date: Wednesday, June 24, 2026
Time: 2:00 – 3:00 PM ET
bit.ly/4ecvJZV
Krish Patel retweeted
This review article from our new Update on Antibody–Drug Conjugates supplement discusses the clinical development and current role of ADCs in the therapeutic landscape of hematologic malignancies.
acsjournals.onlinelibrary.wi…
@OncoAlert @KrishPatelMD @SAStricklandMD @SarahCannonDocs
Looking forward to a really engaging EHA and then post EHA discussion on lots of amazing new data to highlight in hematology! @SarahCannonDocs @SCRIOncology
#lymsm #heme #EHA2026 #research
REGISTER for our Post-EHA 2026 Highlights 🩸
Webinar series by VJHemOnc featuring presentations & discussions on selected abstracts from the 31st Congress of the European Hematology Association (EHA)
📍 Webinar series
🗓️ 23 June-2nd July 2026
Covering:
📌 Lymphoma - Chaired by: @KrishPatelMD
📌 MPNs - Chaired by: @harrisoncn1
📌 AML - Chaired by: @Daver_Leukemia
📌 Myeloma - Chaired by: Dr Karthik Ramasamy
📌 MDS - Chaired by: @Dr_AmerZeidan
📌 CLL - Chaired by: Dr Alexey Danilov
Agendas coming soon! 👀
Secure your spot 🔗 👉 vjhemonc.com/event/post-eha-…
Krish Patel retweeted
Wrapping up strong at #ASCO26 with SCRI Meet the Expert sessions in GI, breast, and innovation in trial delivery through Accelero. Come connect with our teams! @GHannafantastic @MeredithPelster @ErikaHamilton9 @SPremji7866
Krish Patel retweeted
Day 1 of #ASCO26 is almost here. Our experts are presenting the latest research in hematologic disorders & more.
Dr. Hans Lee will share first results from the Phase 1/2 LINKER-AL2 trial.
#SCRI #OncologyLeadership #CancerResearch
Krish Patel retweeted
If you are interested in lymphoma analysis from EHA2026 do sign up - should be good fun! #lymsm #lymphoma vjhemonc.com/event/post-eha-…
Krish Patel retweeted
When U.S. representation in global oncology trials falls short, access and approvals can be affected. Hans Lee MD, (SCRI) highlights the need to expand clinical trial access in community settings.
🔗 sohoinsider.com/news/when-us…
#Oncology #ClinicalTrials #CancerResearch
Krish Patel retweeted
SCRI has enrolled & treated the first patients worldwide in a first‑of‑its‑kind Phase III CAR T‑cell clinical trial for aggressive large B‑cell lymphoma—bringing innovative treatment options to patients through community‑based research. @StDavidsHC #CAR_T #Lymphoma #SCRI
Krish Patel retweeted
Chicago healthcare professionals: join us for Lymphoma Rounds as physicians share best practices and learn the latest information on advances in lymphoma treatment.
Open to currently practicing healthcare professionals ONLY.
Register here: bit.ly/3Qs1WUR
Excited to join a stellar crew of faculty in Nashville for this exciting meeting!
Excited to highlight faculty member Dr. @KrishPatelMD, Director of Lymphoma Research at Sarah Cannon Research Institute and expert medical oncologist at SCRI Oncology Partners in Nashville! With his focus on novel therapeutics, cellular therapies, and clinical trials for lymphomas and CLL, he's delivering game-changing insights to #NashvilleHeme26. FREE registration is still open for this 2-day CE-accredited conference, Feb 26-28, 2026. Secure your spot with code FREECME and join over 60 top experts: na2.hubs.ly/H03qYDn0 #Hematology #CME
Krish Patel retweeted
Join Krish Patel, MD (@KrishPatelMD), and Nirav Shah, MD, MS (@niravshahmd), on 2/05 at 12 PM MST during #Tandem26 for a #Bcell cancers #MedEd event 🔗 bit.ly/CLL-MCLTandem26-T #HemOnc
Krish Patel retweeted
Adapting to Innovation in B-Cell Cancers: Harnessing Therapeutic Advances and Revisiting HCT—join Krish Patel, MD (@KrishPatelMD), and Nirav Shah, MD, MS (@niravshahmd) on 2/05 at 12 PM MST: bit.ly/CLL-MCLTandem26-T #Tandem26 #HemOnc
